D. Tiblalexi

DIFFERENTIAL DIAGNOSIS ISSUES IN NESTED VARIANT OF UROTHELIAL CARCINOMA - CASE REPORT AND LITERATURE REVIEW-

D. Tiblalexi, Despina Tiblalexi, 2014 .

Molecular Evidence-Based Use of Bone Resorption-Targeted Therapy in Prostate Cancer Patients at High Risk for Bone Involvement

M. Koutsilieris, D. Tiblalexi, R. Tenta, 2002, Molecular medicine.

Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria.

D. Tiblalexi, T. Theoharides, N. Papadopoulou, 2005, The Journal of investigative dermatology.

Bone Metastasis Microenvironment Participates in the Development of Androgen Ablation Refractoriness and Chemotherapy Resistance of Prostate Cancer Cells Residing in the Skeleton: Clinical Implications

M. Koutsilieris, D. Tiblalexi, R. Tenta, 2005 .

Bone microenvironment‐related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC‐3 prostate cancer cells

M. Koutsilieris, M. Manoussakis, D. Tiblalexi, 2004, The Prostate.

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

D. Tiblalexi, N. Viniou, P. Diamantopoulos, 2021, Blood advances.

Mechanisms of the Action of Zoledronic Acid on Human MG-63 Osteosarcoma Cells

M. Alexis, M. Koutsilieris, M. Manoussakis, 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.